Physician profile
David Riegleman
NPI 1639527443
$8,299.25
in general payments reported to CMS, 2019-2025
13 companies · $523 in 2025
The $523 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,050 · 2020: $736 · 2021: $399 · 2022: $573 · 2023: $1,621 · 2024: $1,397 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,535 · Travel and Lodging: $5.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,535.45 |
| Travel and Lodging | $5.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,108.58 | 2019-2025 | Proclaim, Eterna |
| Medtronic USA, INC. | $1,301.20 | 2019 | |
| Nevro Corp. | $1,199.68 | 2019-2023 | Senza |
| Saluda Medical Americas, INC. | $710.47 | 2023-2025 | Evoke Scs, Evoke |
| Medtronic, INC. | $607.14 | 2022-2024 | Intellis Adaptivestim, Vanta Adaptivestim |
| Boston Scientific Corporation | $536.71 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Painteq LLC | $483.84 | 2023-2024 | Painteq |
| Spr Therapeutics, INC | $430.74 | 2020-2023 | Sprint Pns System |
| Relievant Medsystems, INC. | $308.43 | 2020-2021 | |
| Mml US, INC. | $221.25 | 2024-2025 | Reactiv8 |
| Biotronik Nro, INC. | $132.45 | 2023 | Biotronik |
| Spinal Simplicity, LLC | $131.79 | 2022 | |
| Sun Pharmaceutical Industries INC. | $126.97 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Riegleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.